PHARMACY MEDICINES (P.) Zimbabwe · MCAZ

CORILIEF DRY COUGH SYRUP

HYDROBROMIDE

2016/22.2.1/5236 SYRUP; ORAL 15 MG/5 ML

What it does

Hydrobromide is a medication used to treat various conditions, often related to respiratory issues.

Commonly used for: coughs, asthma, allergic reactions

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
2016/22.2.1/5236
Registration date
2016-07-27
Expiry date
2030-12-11
Status
PHARMACY MEDICINES (P.)
Active ingredient
HYDROBROMIDE
Dosage form
SYRUP; ORAL
Strength
15 MG/5 ML
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Varichem Pharmaceuticals
Country of origin
-
Manufacturer location
194 Gleneagles Rd, Harare, Zimbabwe

Source: Medicines Control Authority of Zimbabwe · fetched 2026-04-18 08:22:06 · updated 2026-09-30 04:30:04

Disclaimer: This information is sourced from Medicines Control Authority of Zimbabwe (Zimbabwe). Always consult a qualified healthcare professional before using any medication.

About this medicine

Hydrobromide is a medication used to treat various conditions, often related to respiratory issues.

What it treats

  • coughs
  • asthma
  • allergic reactions

How it works

Hydrobromide works by relaxing the muscles in the airways, making it easier to breathe.

Who it's for

It is suitable for adults and children with respiratory problems or allergies.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: hydrobromide

BNF-referenced

Hydrobromide refers to a chemical compound formed when hydrobromic acid reacts with an organic base. It is commonly associated with various drugs that are administered in hydrobromide salt form. These salts enhance the stability and solubility of the active pharmaceutical ingredients. The hydrobromide salts are often used in formulations for their pharmacological effects, particularly in the central nervous system and respiratory conditions.

Indications

  • Respiratory conditions (e.g., asthma, chronic obstructive pulmonary disease)
  • Cough (e.g., as an antitussive)
  • Anxiety and sleep disorders (when associated with specific formulations)

Dosage

Children: Refer to the BNF for Children for appropriate dosing information, as it is determined based on weight and age for the specific formulation.

Adults: Refer to the specific product monograph for dosing information, as it varies based on the drug formulation and indication.

Mechanism of action

Hydrobromides often act as competitive antagonists or agonists at specific receptor sites, depending on the drug involved. The exact mechanism can vary widely, but many hydrobromide-containing drugs modulate neurotransmitter activity, impacting various pathways in the body such as those involved in the central nervous system or respiratory function. The metabolic pathways include Phase I reactions primarily mediated by cytochrome P450 enzymes, which facilitate the functionalization and clearance of these compounds.

Pharmacodynamics

The pharmacodynamics of hydrobromide salts are largely determined by the specific drug they are associated with. Generally, hydrobromides may exhibit effects such as sedation, bronchodilation, or antitussive actions. The efficacy and adverse effects are influenced by the drug's receptor selectivity, affinity, and the pharmacological properties inherent to the parent compound.

Pharmacokinetics

Hydrobromides typically exhibit variable pharmacokinetic profiles depending on the specific drug formulation. They are generally absorbed rapidly following oral administration, with peak plasma concentrations occurring within a few hours. Metabolism primarily occurs in the liver through cytochrome P450 enzymes, particularly CYP2E1, among others. The elimination half-life varies but is often in the range of several hours, allowing for once or twice-daily dosing in many formulations. Excretion is usually via the kidneys, with metabolites being eliminated in urine.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed and the potential benefits justify the potential risks to the fetus.

Breast-feeding

Caution is advised; consider the importance of the drug to the mother against potential risks to the breastfeeding infant.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.

This drug in other countries

The same active ingredient registered across other registries we cover - including different brands.